- Home
- KYTX vs JHS Comparison
KYTX vs JHS Comparison
Compare KYTX & JHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYTX
- JHS
- Stock Information
- Founded
- KYTX 2018
- JHS 1973
- Country
- KYTX United States
- JHS United States
- Employees
- KYTX 119
- JHS N/A
- Industry
- KYTX
- JHS Finance Companies
- Sector
- KYTX
- JHS Finance
- Exchange
- KYTX NYSE
- JHS Nasdaq
- Market Cap
- KYTX 150.0M
- JHS 131.4M
- IPO Year
- KYTX 2024
- JHS N/A
- Fundamental
- Price
- KYTX $2.81
- JHS $11.33
- Analyst Decision
- KYTX Strong Buy
- JHS
- Analyst Count
- KYTX 5
- JHS 0
- Target Price
- KYTX $19.00
- JHS N/A
- AVG Volume (30 Days)
- KYTX 603.2K
- JHS 32.8K
- Earning Date
- KYTX 08-11-2025
- JHS 01-01-0001
- Dividend Yield
- KYTX N/A
- JHS 3.96%
- EPS Growth
- KYTX N/A
- JHS N/A
- EPS
- KYTX N/A
- JHS 0.02
- Revenue
- KYTX N/A
- JHS N/A
- Revenue This Year
- KYTX N/A
- JHS N/A
- Revenue Next Year
- KYTX N/A
- JHS N/A
- P/E Ratio
- KYTX N/A
- JHS $553.50
- Revenue Growth
- KYTX N/A
- JHS N/A
- 52 Week Low
- KYTX $1.78
- JHS $9.76
- 52 Week High
- KYTX $11.40
- JHS $11.25
- Technical
- Relative Strength Index (RSI)
- KYTX 46.72
- JHS 63.63
- Support Level
- KYTX $2.71
- JHS $11.06
- Resistance Level
- KYTX $3.75
- JHS $11.45
- Average True Range (ATR)
- KYTX 0.31
- JHS 0.08
- MACD
- KYTX -0.08
- JHS 0.03
- Stochastic Oscillator
- KYTX 9.62
- JHS 70.95
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
About JHS John Hancock Income Securities Trust
John Hancock Income Securities Trust is a United States-based closed-ended diversified management investment company. Its primary objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.